JP2008517991A5 - - Google Patents

Download PDF

Info

Publication number
JP2008517991A5
JP2008517991A5 JP2007538524A JP2007538524A JP2008517991A5 JP 2008517991 A5 JP2008517991 A5 JP 2008517991A5 JP 2007538524 A JP2007538524 A JP 2007538524A JP 2007538524 A JP2007538524 A JP 2007538524A JP 2008517991 A5 JP2008517991 A5 JP 2008517991A5
Authority
JP
Japan
Prior art keywords
effective amount
therapeutically effective
pld
combination
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007538524A
Other languages
English (en)
Japanese (ja)
Other versions
JP4554684B2 (ja
JP2008517991A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2005/050189 external-priority patent/WO2006046080A2/en
Publication of JP2008517991A publication Critical patent/JP2008517991A/ja
Publication of JP2008517991A5 publication Critical patent/JP2008517991A5/ja
Application granted granted Critical
Publication of JP4554684B2 publication Critical patent/JP4554684B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007538524A 2004-10-26 2005-10-26 抗癌治療 Expired - Lifetime JP4554684B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62216304P 2004-10-26 2004-10-26
PCT/GB2005/050189 WO2006046080A2 (en) 2004-10-26 2005-10-26 Pegylated liposomal doxorubicin in combination with ecteinescidin 743

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009219607A Division JP2009292850A (ja) 2004-10-26 2009-09-24 抗癌治療

Publications (3)

Publication Number Publication Date
JP2008517991A JP2008517991A (ja) 2008-05-29
JP2008517991A5 true JP2008517991A5 (https=) 2008-11-13
JP4554684B2 JP4554684B2 (ja) 2010-09-29

Family

ID=36096124

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007538524A Expired - Lifetime JP4554684B2 (ja) 2004-10-26 2005-10-26 抗癌治療
JP2009219607A Pending JP2009292850A (ja) 2004-10-26 2009-09-24 抗癌治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009219607A Pending JP2009292850A (ja) 2004-10-26 2009-09-24 抗癌治療

Country Status (26)

Country Link
US (1) US20090117176A1 (https=)
EP (1) EP1827500B1 (https=)
JP (2) JP4554684B2 (https=)
KR (1) KR101287918B1 (https=)
CN (1) CN101119750B (https=)
AT (1) ATE430586T1 (https=)
AU (1) AU2005298364B2 (https=)
BR (1) BRPI0518250A2 (https=)
CA (1) CA2582452C (https=)
CY (1) CY1110329T1 (https=)
DE (1) DE602005014380D1 (https=)
DK (1) DK1827500T3 (https=)
ES (1) ES2326825T3 (https=)
HR (1) HRP20090345T1 (https=)
IL (1) IL182352A (https=)
MX (1) MX2007004744A (https=)
NO (1) NO328958B1 (https=)
NZ (1) NZ554765A (https=)
PL (1) PL1827500T3 (https=)
PT (1) PT1827500E (https=)
RS (1) RS50822B (https=)
RU (1) RU2359700C2 (https=)
SI (1) SI1827500T1 (https=)
UA (1) UA87877C2 (https=)
WO (1) WO2006046080A2 (https=)
ZA (1) ZA200703396B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
HRP20080598T3 (en) 2003-11-13 2009-01-31 Pharma Mar Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
ATE368461T1 (de) 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US8444963B2 (en) 2006-06-19 2013-05-21 John Hopkins University Tumor specific delivery of therapeutic agents via liposomase
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
EP3518931A4 (en) * 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
RU2657835C1 (ru) * 2017-11-28 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ получения системы для доставки противоопухолевого препарата в клетки опухоли

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
BR9909488B1 (pt) * 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
JP2004506430A (ja) * 2000-08-11 2004-03-04 シティ・オブ・ホープ Ｓｘｒによるトランス活性化の抗新生物剤ｅｔ−７４３による阻害
NZ525243A (en) * 2000-10-31 2005-01-28 Pharma Mar S A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
MXPA03007989A (es) * 2001-03-06 2003-12-04 Bristol Myers Squibb Co Metodo y forma de dosificacion para tratamiento de tumores por administracion de tegafur, uracil, acido folinico, paclitaxel y carboplatin.
KR100915741B1 (ko) * 2001-06-15 2009-09-04 코너스톤 파마슈티칼스 표적 조직 및 세포를 치료하기에 유용한 나노입자를함유하는 약제학적 및 진단학적 조성물
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
US20040082856A1 (en) * 2002-07-16 2004-04-29 Alfred E. Mann Institute For Biomedical Engineering, University Of Southern California Support bra for ultrasonic breast scanner
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
HRP20080598T3 (en) * 2003-11-13 2009-01-31 Pharma Mar Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20050129752A1 (en) * 2003-12-15 2005-06-16 Tty Biopharm Limited Company Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
WO2006005602A2 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
ES2361566T3 (es) * 2005-11-25 2011-06-20 Pharma Mar S.A., Sociedad Unipersonal Uso de inhibidores de parp-1.
US20080075772A1 (en) * 2006-04-13 2008-03-27 Lawrence Solomon Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
CA2652035A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments

Similar Documents

Publication Publication Date Title
JP6404242B2 (ja) がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
JP2009539769A5 (https=)
JP2008517991A5 (https=)
NZ514464A (en) Apomorphine and sildenafil composition
KR101900520B1 (ko) 복합 조성물
JP2010519224A5 (https=)
JP2002544231A5 (https=)
JP2008520544A5 (ja) 癌関連疲労の治療または予防のための医薬の製造への使用方法
JP2006514092A5 (https=)
JP2009515901A5 (https=)
CA2582452A1 (en) Pegylated liposomal doxorubicin in combination with ecteinascidin 743
RU2007101695A (ru) Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
JP2009536956A5 (https=)
JP2005508963A5 (https=)
JP2008540364A5 (https=)
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
JP2003514025A5 (https=)
ES2267841T3 (es) Uso de una derivado de alfa-halogeno-acriloil distamicina para la preparacion de un medicamento para el tratamiento del cancer.
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
JP2002540148A5 (https=)
CA2519789A1 (en) Aplidine for multiple myeloma treatment
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
JP2015510945A5 (https=)
RU2010140888A (ru) Улучшенные противораковые терапии